Anthem Biosciences Limited – Investor Presentation Summary

Key Operational Highlights

  • Consolidated Revenue from Operations reached ₹5,940 Mn in Q2FY27, a 7.9% YoY growth from ₹5,505 Mn in Q2FY26.
  • CRDMO business delivered revenues of ₹5,093 Mn, a 9.2% YoY growth from ₹4,662 Mn in Q2FY26.
  • Specialty Ingredients segment delivered revenues of ₹848 Mn, a slight 0.6% YoY growth from ₹843 Mn in Q2FY26.
  • Key drivers of operational performance include strong underlying demand in the CRDMO business stream, strict cost discipline, yield optimization, and improved workforce productivity.

Segment-wise Performance

  • CRDMO Segment: Q2FY27 revenue ₹5,093 Mn (9.2% YoY growth); H1FY27 revenue ₹8,501 Mn (-7.6% YoY)
  • Specialty Ingredients Segment: Q2FY27 revenue ₹848 Mn (0.6% YoY growth); H1FY27 revenue ₹1,622 Mn (-5.6% YoY)
  • Explanation of significant changes: CRDMO segment showed strong quarterly growth while Specialty Ingredients remained relatively flat year-over-year.

Financial Highlights

Q2FY27 Performance:

  • Revenue: ₹5,940 Mn
  • EBITDA: ₹3,304 Mn
  • PAT: ₹2,115 Mn
  • EPS: Not Specified
  • Margins: EBITDA Margin 50.6%, PAT Margin 32.4%
  • YoY comparison: Revenue up 7.9%, EBITDA up 24.1%, PAT up 21.9%
  • QoQ comparison: Revenue up 42.0% from Q1FY27 (₹4,182 Mn), EBITDA up 88.3% from Q1FY27 (₹1,755 Mn), PAT up 76.3% from Q1FY27 (₹1,199 Mn)

H1FY27 Performance:

  • Revenue: ₹10,123 Mn
  • EBITDA: ₹5,059 Mn
  • PAT: ₹3,314 Mn
  • Margins: EBITDA Margin 46.2%, PAT Margin 30.2%
  • YoY comparison: Revenue down -7.2% from H1FY26 (₹10,914 Mn), EBITDA up 5.3% from H1FY26 (₹4,805 Mn), PAT up 7.2% from H1FY26 (₹3,092 Mn)

Drivers of financial performance: Significant margin expansion due to cost efficiencies, yield optimization, workforce productivity improvements, and lower cost of materials consumed (-17.3% YoY in Q2). Other income contributed significantly with ₹589 Mn in Q2FY27 (23.3% YoY growth).

Comparison to market estimates: Not Specified

Key Risks: Not explicitly disclosed in the presentation

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not Specified

Balance Sheet Snapshot

  • Net Cash position: ₹15,380 Mn as of September 30, 2026
  • Net Debt/Equity: Not Specified (implied negative net debt due to cash position)
  • Reserves: Not Specified
  • Current Assets/Liabilities: Not Specified
  • Working Capital/Leverage Metrics: Not Specified
  • Financial Health Insights: Strong cash position indicates healthy liquidity

Capex & Cash Flow Health

  • Capital Expenditure: Not Specified
  • Free Cash Flow: Not Specified
  • Operating Cash Flow: Not Specified
  • Net Debt Movement: Not Specified (but net cash position of ₹15,380 Mn reported)
  • Investment Rationale: Not Specified

Strategic & R&D Initiatives

  • Investments in Innovation: Not Specified
  • Expected impact on growth: Not Specified
  • Strategic Rationale: Focus on sustaining industry-leading margins through cost discipline and operational efficiencies

Industry Trends & Business Environment

  • Macro/Industry Trends: Underlying demand remains strong according to management commentary
  • Impact on Company: Strong demand environment supporting CRDMO business growth

Management Commentary & Growth Outlook

  • Strategic Outlook: "We are confident in our ability to sustain growth and create long-term value for all stakeholders" - Ajay Bhardwaj, Chairman, MD & CEO
  • FY Guidance: Not explicitly provided, but management expressed confidence in sustaining current performance "all year"
  • Market Share Targets: Not Specified
  • Risks and Opportunities: Management highlighted maintaining cost efficiencies, yield optimization, and workforce productivity as key to sustaining margin performance